WallStSmart

AbbVie Inc (ABBV)vsInteger Holdings Corp (ITGR)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

AbbVie Inc generates 3285% more annual revenue ($62.82B vs $1.86B). ITGR leads profitability with a 7.6% profit margin vs 5.8%. ABBV appears more attractively valued with a PEG of 0.57. ABBV earns a higher WallStSmart Score of 63/100 (C+).

ABBV

Buy

63

out of 100

Grade: C+

Growth: 4.0Profit: 8.0Value: 4.0Quality: 5.0
Piotroski: 5/9Altman Z: 0.40

ITGR

Buy

62

out of 100

Grade: C+

Growth: 7.3Profit: 5.5Value: 7.3Quality: 6.5
Piotroski: 3/9Altman Z: 1.97
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABBVSignificantly Overvalued (-19.7%)

Margin of Safety

-19.7%

Fair Value

$168.33

Current Price

$201.55

$33.22 premium

UndervaluedFair: $168.33Overvalued
ITGRUndervalued (+33.0%)

Margin of Safety

+33.0%

Fair Value

$130.14

Current Price

$88.12

$42.02 discount

UndervaluedFair: $130.14Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABBV5 strengths · Avg: 9.6/10
Market CapQuality
$358.55B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
62.3%10/10

Every $100 of equity generates 62 in profit

Operating MarginProfitability
31.6%10/10

Strong operational efficiency at 31.6%

Debt/EquityHealth
-21.0610/10

Conservative balance sheet, low leverage

PEG RatioValuation
0.578/10

Growing faster than its price suggests

ITGR2 strengths · Avg: 9.0/10
EPS GrowthGrowth
52.9%10/10

Earnings expanding 52.9% YoY

Price/BookValuation
1.8x8/10

Reasonable price relative to book value

Areas to Watch

ABBV4 concerns · Avg: 2.3/10
Profit MarginProfitability
5.8%3/10

5.8% margin — thin

P/E RatioValuation
98.9x2/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-45.8%2/10

Earnings declined 45.8%

Altman Z-ScoreHealth
0.402/10

Distress zone — elevated risk

ITGR4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.5%4/10

0.5% revenue growth

Altman Z-ScoreHealth
1.974/10

Grey zone — moderate risk

Profit MarginProfitability
7.6%3/10

7.6% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : ABBV

The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.57 suggests the stock is reasonably priced for its growth.

Bull Case : ITGR

The strongest argument for ITGR centers on EPS Growth, Price/Book. PEG of 1.37 suggests the stock is reasonably priced for its growth.

Bear Case : ABBV

The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 98.9x leaves little room for execution misses.

Bear Case : ITGR

The primary concerns for ITGR are Revenue Growth, Altman Z-Score, Profit Margin.

Key Dynamics to Monitor

ITGR carries more volatility with a beta of 0.66 — expect wider price swings.

ABBV is growing revenue faster at 12.4% — sustainability is the question.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ABBV scores higher overall (63/100 vs 62/100) and 12.4% revenue growth. ITGR offers better value entry with a 33.0% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AbbVie Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.

Integer Holdings Corp

HEALTHCARE · MEDICAL DEVICES · USA

Integer Holdings Corporation is an outsourced manufacturer of medical devices in the United States, Puerto Rico, Costa Rica, and internationally. The company is headquartered in Plano, Texas.

Want to dig deeper into these stocks?